Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

Cannabis use is associated with higher inflammation after EoE treatment, which may indicate a negative effect.

The 6-food elimination diet (SFED) is the most cost-effective first-line treatment for eosinophilic esophagitis (EoE) from a financial standpoint. However, proton pump inhibitors (PPIs) are the most ...

In cases where no other manifestation of lichen planus are found and direct immunofluorescence for fibrinogen along the basement membrane is negative, the term “lichenoid esophagitis ... Histology of ...

improved symptoms and reduced esophageal eosinophil counts in adult and adolescent patients with eosinophilic esophagitis (EoE), according to interim results of a pivotal phase 3 trial.

The hospital said they discovered an issue with how a solution was put through a scope during some endoscopy procedures. When Johnny Mozingo got a colonoscopy back in July, he did not expect to ...

eosinophilic esophagitis or, less likely, a hypersecretory syndrome or a genotype that confers altered metabolism of PPIs. Refractory reflux syndromes associated with normal endoscopy findings are ...

In tandem with its regulatory filings, Eupraxia Pharmaceuticals has reported promising data from its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment candidate for eosinophilic esophagitis (EoE).